Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in ...

Gilead Science’s Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on ...

Illumina has begun rolling out its protein research platform, powered in part by tech from SomaLogic, which the DNA ...

After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data ...

Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking ...

The FDA has outlined a new review process for drugs and biologics designed to treat ultra-rare genetic diseases that would ...

Kardium has collected an FDA approval for its pulsed field ablation approach to treating atrial fibrillation, giving it the ...

Novartis has returned to Argo Biopharmaceutical with $160 million in upfront cash to explore various cardiovascular meds in the Chinese biotech’s siRNA pipeline.

Treeline Biosciences has surfaced from secrecy, producing a $200 million series A extension and picking three ripe programs for the clinic. The extra cash brings the Massachusetts-based oncology ...

Boston-based Radiance Biopharma is doling out $15 million cash and offering over $1 billion in milestones for licensing ...

After throwing down $70 million upfront to partner on Black Diamond Therapeutics’ solid tumor candidate earlier this year, ...

After demonstrating last year that its miniaturized heart pumps could improve survival shortly after a serious heart attack, ...